Open label, single-arm, phase IIIb clinical trial to evaluate the safety of switching from intravenous rituximab to subcutaneous rituximab during first line treatment for CD20+ Non-Hodgkin's follicular lymphoma and diffuse large B-cell lymphoma.

Trial Profile

Open label, single-arm, phase IIIb clinical trial to evaluate the safety of switching from intravenous rituximab to subcutaneous rituximab during first line treatment for CD20+ Non-Hodgkin's follicular lymphoma and diffuse large B-cell lymphoma.

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Aug 2017

At a glance

  • Drugs Rituximab (Primary)
  • Indications Diffuse large B cell lymphoma; Follicular lymphoma
  • Focus Adverse reactions
  • Acronyms MabRella
  • Sponsors Roche
  • Most Recent Events

    • 10 Aug 2017 Status changed from active, no longer recruiting to completed.
    • 25 Jun 2017 Results of safety analysis (n=421) from MabRella study (NCT01889069; NCT01987505; NCT02406092), presented at the 22nd Congress of the European Haematology Association.
    • 06 Dec 2016 Pooled interim analysis data of this trial and two other trials (NCT01889069 and NCT02406092) presenting safety data were presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top